September 15, 2014 8:19 AM | 1 min read
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
In a report published Monday, Credit Suisse analyst Ravi Mehrotra reiterated an Outperform rating on
Receptos (NASDAQ: RCPT), and raised the price target from $58.00 to 75.00.In the report, Credit Suisse noted, “Even further granularity of the RADIANCE PII data for RPC1063 in relapsing multiple sclerosis (RMS) were presented at the leading oral ‘Late Breaking News' presentation on Saturday, September 13, 2014 at ACTRIMS-ECTRIMS 2014. The slides from this presentation are included in this note. RCPT will hold an investor call/webcast at 8:30am ET on Monday, September 15, 2014 (US: 866-757-6808 / Int'l: 760-536-5211 / Passcode: 2249659). The granularity of the data further support our RPC1063 ‘significant differentiation thesis' and raise a super bull view of possible ultimate differentiation on superior efficacy as well as side effect profile. Accordingly, we are increasing our TP to $75 (previously $58) based on RCP1063 total franchise sales of $2.0B vs. $1.5B previously.”Receptos closed on Friday at $59.67.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.